September 22, 2018
Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of adverse events (AEs) in patients with relapsed or refractory multiple myeloma (MM), according to final results from the phase III ASPIRE trial.1 “At interim analysis … the addition of carfilzomib significantly improved progression-free survival (PFS) compared...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand